We stand at the forefront of aesthetic biotechnology, where groundbreaking scientific discoveries meet clinical excellence. Our dedicated team of molecular biologists, dermatologists, and formulation scientists work tirelessly to develop the next generation of skin rejuvenation solutions that set new standards in safety, efficacy, and natural-looking results.

Our Scientific Approach

Advanced Hyaluronic Acid Technology

• Utilizing patented cross-linking methods that create ultra-stable HA matrices
• Multi-weight formulations (low, medium, and high molecular weight) for comprehensive skin hydration
• Precision-engineered for optimal tissue integration and longevity (up to 24 months)

Bioactive Signaling Molecules

• Proprietary peptide complexes that stimulate collagen I/III production
• Growth factor analogs that activate skin stem cells
• Smart delivery systems ensuring targeted action in specific skin layers

Rigorous Clinical Validation

• All formulations undergo extensive preclinical testing
• Multi-center clinical trials across Europe and Asia
• Continuous post-market surveillance for long-term safety data

Our Research Facilities

Our state-of-the-art laboratories in Istanbul feature:

• ISO 13485-certified clean rooms
• Advanced analytical equipment (HPLC, mass spectrometry)
• 3D skin tissue culture systems for efficacy testing
• Robotic formulation systems ensuring batch-to-batch consistency

Recent Breakthroughs

Matrix® Bio-Regeneration System

• Tri-phasic hyaluronic acid complex
• 8-signal peptide cocktail
• Cellular energy boosters (NAD+ precursors)

NanoHA™ Delivery Platform

• Sub-50nm HA particles for transdermal delivery
• Demonstrated 300% better absorption in clinical studies
• Ideal for sensitive areas like the periorbital region

For Medical Professionals

• Hands-on product application masterclasses
• Access to our digital knowledge base (100+ clinical papers)
• Custom treatment protocol development
• 24/7 access to our scientific advisory team

Commitment to Innovation

With 15% of annual revenue reinvested in R&D, we’re currently developing:

• Next-generation bio-stimulatory fillers
• Gene expression-modulating serums
• AI-assisted treatment planning systems